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Background and Methods: We analyzed the late outcome of
long-term survivors of allogeneic stem cell transplantation (allo-
SCT) treated by the Leukemia/Bone Marrow Transplant Program
of British Columbia. Results: We reviewed the charts of 430
patients (pts) who received allo-SCT between 1981 and 2002 for
hematologic malignancies and who were free of their primary
disease for at least two years after transplant. Late recurrent pri-
mary malignancy was found in 13% (57 pts) of allo-SCT recipients
and was the primary cause of late death. 31 (7%) allo-SCT recip-
ients died of non-relapse causes at a median of 5.5 year (range 2 to
15.6) post allo-SCT. Non relapse causes of death were GVHD (11
pts), second cancer (8), coronary disease (3), infection (2), miscel-
laneous (5), and unknown (2). 342 non relapse long-term allo-SCT
survivors were evaluated for late complications. Median follow-up
for the survivors was 8 (range 2 to 23) years. Chronic graft versus
host disease (cGVHD) was diagnosed in 205 (60%) survivors with
more than 50% of pts still having symptoms of cGVHD at last
follow-up. Cardiovascular complications in survivors included hy-
pertension (21%), coronary disease (3%) and myocardial infarction
(2%). Renal failure was diagnosed in 64 (17%) survivors; it resolved
over time in 17 pts; 6 pts needed dialysis. Endocrine complications
seen in survivors included dyslipidemia (10%), hypothyroidism
(9%), diabetes (7%), osteopenia/osteoporosis (25%), hypogonad-
ism in females (76%) and hypogonadism in males (7%). Depres-
sion was reported in 41 (11%) survivors, and 2 pts attempted
suicide. Cognitive impairment and other psychiatric problems
were identiﬁed in 2% and 3% respectively. Sexual dysfunction was
reported in 6% of survivors. Conclusions: In patients who receive
allo-SCT as treatment for hematologic malignancy and who are
disease-free 2 years post transplant, probability of durable remis-
sion is high with acceptable but deﬁnite late toxicity. The occur-
rence of late events necessitates lifelong medical surveillance.
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SECOND SOLID CANCERS AFTER ALLOGENEIC STEM CELL TRANSPLAN-
TATION: THE VANCOUVER EXPERIENCE
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The development of second solid cancers in recipients of hema-
topoietic stem cell transplants (SCT) represents a serious compli-
cation among long term survivors. To assess the incidence and
associated risk factors for second solid cancers following allogeneic
SCT, we performed a retrospective analysis of 926 consecutive
patients (pts) who underwent an allogeneic SCT between January
1985 and December 2003. Primary diagnoses were AML (235),
ALL (103), CML (216), lymphoproliferative disorders (150), MDS
(96), MM (80), or other (46). Median age at SCT was 39 years
(range 12–65) and median time from diagnosis to SCT was 5.1
months (range 0.2–345). Six hundred forty pts had a sibling donor
and 286 had an unrelated donor. Stem cell source was bone mar-
row (810), peripheral blood (109), or both (7). Conditioning reg-
imens were: TBI-based (488), BuCy other (414), other (24). The
graft was T cell depleted in 43 pts. With a median follow-up of
22.2 months post SCT (range 0.07–230.5) for all 926 pts and 84.2
months (range 8.4–230.5) for surviving pts, 30 solid malignancies
have occurred in 28 pts at a median of 81.4 months post SCT
(range 1.4–207.5). These second tumors involved skin (8 basal cell
carcinoma, 4 invasive squamous cell carcinoma), lung (5), oral
cavity (4), colon (2), bladder (2) breast (1), kidney (1), parotid gland
(1), vulva-in situ (1), and primary unknown (1). Of the 28 pts, 6
died from the second cancer at a median of 6.1 months (range
0.9–36) following the diagnosis. The 10-year cumulative incidence
of all second solid cancers was 3.1% (95% CI 2–5%). Compared to
age and gender adjusted cancer rates in the general population of
BC, the relative risk (RR) of developing a second solid cancer after
allografting excluding nonmelanoma skin cancer was 1.85 (95% CI
1.04–3.06), P  .019. In multivariate analysis, signiﬁcant risk
factors were recipient age at SCT 	 40 years (RR 4.8), P .01 and
donor gender [female donor/male recipient (RR 5.4), female do-
nor/female recipient (RR 2.3)] P .002. We conclude that alloge-
neic SCT recipients are at an increased risk of developing a second
solid cancer compared to the general population, particularly if the
recipient is 	40 years old at the time of allografting. It is also
apparent that male recipients of a female graft have a higher risk of
second solid cancers. Longer follow-up is needed to more fully
assess the incidence and risk factors for second solid tumors post-
transplant due to their long latency period.
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Bone marrow transplantation (BMT) is the treatment of choice
for many patients with malignant and non-malignant diseases. As
the survival of these patients increases, long term complications
such as osteoporosis should be considered, because it associates
with morbidity and mortality of the patients directly. We have
prospectively investigated 63 patients undergoing BMT for acute
and chronic leukemia and lymphoma. Bone mineral density (BMD)
was measured with dual X-ray absorptiometry before BMT, 6 and
12 months later also. Osteocalsin and bone alkaline phosphatase as
markers of bone formation and c-terminal telopeptides of type 1
collagen as a marker of bone resorption were assessed. Moreover,
serum concentration of calcium, phosphorous, vitamin D, PTH,
and sex hormones (FSH, LH, testostorone, estradiol) were mea-
sured. There was signiﬁcant decrease in BMD of femoral neck 6
months after BMT (0.06 gr/cm2 in allogenic and 0.04 gr/cm2 in
autologous) but no considerable changes were seen in lumbar
vertebrae. Also, more decrease in bone loss between sixth and
twelfth months was not observed. After one year the rate of os-
teopenia and osteoporosis increased in allogenic and autologous
BMT 10% and 20%, respectively. There was signiﬁcant increase in
the marker of bone resorption but bone formation markers not
only decreased but also increased at the same time. No distinct
difference was observed in serum biochemical turnover markers
between males and females, or between autologous and allogenic
BMT patients. Seventy-six and 90% of the women went into
menopausal state in 6 and 12 months after BMT, respectively, but
male sex hormones did not change considerably. In conclusion, the
risk of bone loss in both allogenic and autologous BMT is higher
in femoral neck rather than lumbar vertebrae and it occurred
mainly in the ﬁrst 6 months after BMT. Preventional and clinical
procedures should be considered.
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Introduction: Despite recent advances in diagnosis and treat-
ment, invasive Aspergillosis (IA) remains a signiﬁcant threat to
hematopoietic stem cell transplant (HSCT) patients. It is estimated
that over 90% of undiagnosed and untreated cases of IA result in
death. Because anti-fungal drug susceptibility varies between the
Aspergillus species, species-speciﬁc identiﬁcation improves the IA
disease management signiﬁcantly. Recently, real time PCR assays
have been reported in diagnosing IA, however, these assays lack
speciﬁcity. Using scorpion technology, we developed a rapid, sen-
sitive, and quantitative real time PCR assay for species-speciﬁc
identiﬁcation of Aspergillus infections that does not cross-react with
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other fungi including Penicillium. Methods: We developed a set of
real-time PCR assays for species-speciﬁc detection of 5 medically
important species (A. fumigatus, A. ﬂavus, A. nidulans, A. niger, A.
terreus) that covers 	99% of all Apsergillus infections. In addition
to BLAST analysis, we evaluated cross-reactivity with other As-
pergillus species, and other fungi. Blood specimens were spiked
with serially diluted conidia to establish the dynamic range of
detection. Additionally, to evaluate the clinical utilities of these
assays, we retrospectively analyzed blood from 60 HSCT patients
whose specimens were sent for routine CMV testing. Results: We
identiﬁed individual ITS1 regions that are speciﬁc for each of the
5 Aspergillus species but are conserved among the strains within the
species. Using scorpion technology, each assay ampliﬁed and de-
tected the species-speciﬁc sequence only and no cross-reactivity
was detected when it was challenged with other fungal genomic
DNA. These assays can detect as few as 100 conidia/mL of whole
blood. Of 60 patients analyzed, 2 patients (3%) were Aspergillus-
positive. One patient was positive for A. ﬂavus (1.11 &ttimes; 103
copies/mL), and 1 patient was coinfected with A. ﬂavus (6.40 102
copies/mL) and A. niger (2.70  103 copies/mL). Conclusions:
Developing a real time PCR assay for species-speciﬁc identiﬁcation
of Aspergillus is a major challenge because of signiﬁcant genomic
sequence homology among thousands of common environmental
fungi such as Penicillium. Using scorpion real time PCR assays, we
have identiﬁed Aspergillus infections at the species level in HSCT
patients. Currently, we are evaluating diagnostic utilities of these
assays on retrospective and prospective HSCT patients.
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ROLE OF QUANTITATIVE VIRAL LOAD MONITORING OF BK VIRUS IN
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Background: Hemorrhagic cystitis (HC) causes signiﬁcant mor-
bidity in hematopoietic stem cell transplantation (HSCT) patients
that could often be life-threatening in post-engraftment. Its inci-
dence varies from 7 to 68%. Polyoma virus BK (BKV) is known to
be associated with the development of HC, however, its diagnosis
could be difﬁcult. We developed a rapid, sensitive, speciﬁc, and
quantitative real time PCR assay and used it for monitoring BKV
infections in HSCT patients with HC. Methods: Primers and a
TaqMan® probe were designed to speciﬁcally amplify and detect
an 83-bp fragment of the BKV Agno gene. We used this assay to
detect and monitor BKV infections in 421 clinical specimens from
86 BMT patients with HC. Results: The real time quantitative
BKV PCR assay is speciﬁc and does not cross-react with other
viruses. Out of 421 clinical specimens from 86 BMT patients, 134
plasma specimens were from 35 patients, 283 urine specimens were
from 78 patients, 4 tissue specimens were from 4 patients, and 27
patients had both urine and plasma specimens. Overall 288 (68%)
specimens from 65 patients (76%) were positive for BKV. More
speciﬁcally, out of 35 patients with plasma specimens, 18 (51%)
had viremia, and out of 78 patients with urine specimens, 62 (79%)
had viruria. Of the 27 patients with both plasma and urine, 14
(52%) had both viruria and viremia, and 12 (44%) had viruria. Two
patients with viruria and viremia also had BKV in tissue, while
another 2 patients with viruria, but not viremia, were negative in
tissue. Urine viral loads (range 2.5  102–9.9  107, mean 7.7 
107, median 1.6  106) were signiﬁcantly higher than plasma
(range 4.0  102–1.5  106, mean 1.2  106, median 6.1  104).
Nineteen patients with HC serially monitored for BKV infections
for over 3 months showed correlations between BKV loads and
clinical symptoms. Interestingly, 4 patients had viruria with in-
creasing BKV loads that ended up with viremia later, indicating
that early BKV screening of urine may provide an early diagnosis
so that treatment therapy can be instituted to avoid severe HC
complications in HSCT patients. Conclusions: Real time BKV
PCR assay provides a rapid, sensitive, and speciﬁc diagnosis of
BKV infections in HC complicating HSCT patients. Furthermore,
quantitative monitoring helps in determining the severity of infec-
tions and measuring the effectiveness of treatment therapy. Cur-
rently, we are monitoring BKV infections in a controlled study on
HSCT patients with HC.
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Purpose: We have programmed a study to evaluate the differ-
ence in health-related quality of life (QOL) in stem cell transplant
donors harvested by marrow aspiration (BM) or by blood apheresis
after peripheral stem cell mobilization with G-CSF (PB). Meth-
ods: Seventy-four healthy sibling donors from 6 institutes entered
the study. The method of harvest was voluntarily selected by each
donor after information about risks and beneﬁts of both proce-
dures. Standard laboratory tests and subjective QOL assessments
by Short-Form 36 (SF36) were performed 4 times; on the day
before operation or G-CSF administration, the seventh day, the
fourth week, and 3 months after harvest. SF 36 includes 8 catego-
ries of assessment; physical functioning (PF), role-physical (RP),
role-emotional (RE), body pain (BP), general health perception
(GH), vitality (VT), social functioning (SF), and mental health
(MH). Results: Thirty-two BM donors and 42 PB donors entered.
When QOL assessments before procedure were compared, scores
of PF, RP, BP, SF, RE, and MH were lower (P  .05, by Mann-
Whitney test) in BM donors than in PB ones. Lowest scores of
QOL were observed on the seventh day after procedures in both
groups. Statistical differences of scores were signiﬁcant in PF
(65.7  10.2 vs 90.8  14.5), RP (50.5  27.9 vs 83.8  22.2), RE
(54.5  30.2 vs 85.1  19.9), VT (54.4  23.2 vs 68.0  25.1), SF
(61.5 26.5 vs 84.6 20.1), and MH (67.6 19.6 vs 78.8 16.0)
between two groups (BM vs PB, respectively). Scores of QOL
returned to the base value at the fourth week in both groups. QOL
scores of PF, RP, SF, and MH were higher than the base value by
paired t-test in BM donors at 3 months after harvest. Discussion:
Previous blood storage and mental stress before anesthesia and
operation appeared to be the causes of decrease in QOL scores
before harvest in BMT donors. Decrease in scores of PF, RP, BP,
and RE at the seventh day indicates both procedures provide
physical stress on donors, however, grade of decrease was higher in
BM donors than in PB donors.Conclusions: BM donors feel more
stress on emotion and mental health as well as physical condition
than PB donors.
317
EXTRACORPOREAL PHOTOPHERESIS (ECP) IN CHILDREN WITH RE-
FRACTORY CHRONIC GVHD: FEASIBILITY AND EFFICACY
Browning, B.1, Collins, J., Thormann, K.1, Duerst, R.1, Kletzel, M.1,
Jacobsohn, D.1 Northwestern University / Children’s Memorial Hospi-
tal, Chicago, IL.
Since 2003, we have used ECP for salvage therapy of pediatric
cGVHD. We developed an algorithm for children of different
weights to guide the need for pRBC transfusion prior to ECP: if
	40 kg, transfuse for hematocrit (hct) 26%; if 25–40 kg, trans-
fuse for hct 32%, if 25 kg, transfuse for hct 35%. Extracor-
poreal Volume (ECV) is graphed and maximum number of cycles
and bowl size is determined. Generally, the 125 mL bowl is used.
Patients 25 kg receive NS bolus prior to ﬁrst cycle and prior to
second cycle as needed. Volume of NS bolus is calculated as
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